skip to content

DIY Investing Doesn't Mean Do-It-Alone

Independent stock and market research on growth and dividend stocks.

Get instant access to:

  • Research on over 50 Growing and Quality Canadian stocks
  • Model Portfolios
  • Investor Q&A, Alerts, and Forums
  • Portfolio Analysis and Tracking Tools

Become a Member

Peter Hodson and Ryan Modesto

5i Recent Blog Posts


Headline image for Finding the Ultimate ETF

Finding the Ultimate ETF

In early January, we released a special report to our ETF & Fund Update members simulating an "ETF Tournament" of the top ETFs in 16 categories we selected throughout 2020. Read through the report to see which ETF comes out on top as the "Ultimate ETF" for Canadian investors. 

Moez M Jan 19, 2021
5i Recent Questions
5i Recent Reports
Rating
B

Review of K-Bro Linen Inc.

JAN 14, 2021 - KBL will continue to benefit from being a larger player in a fragmented space. However, growth outlook is uncertain, particularly in the hospitality segment. We think a B rating remains appropriate.

Download Report
Rating
B+

Review of Leon's Furniture

JAN 14, 2021 - In these circumstances, a rating of B+ is indicated for those who want a stable company that has the ability to generate value for shareholders in the long-term.

Download Report
Rating
B+

Review of Park Lawn Corporation

DEC 21, 2020 - The recent context of the pandemic is forcing individuals to evaluate post-death options boosting PLC's volume growth. The near-term outlook remains solid with abundant M&A opportunities. Rating maintained at 'B+'.

Download Report
Rating
B

Review of H&R Real Estate Investment Trust

DEC 21, 2020 - Shares have some recovery potential as vaccine boosts investor confidence in REITs exposed to retail and office space. HR has a visible pipeline ahead improving its NAV and FFO. Rating maintained at 'B'.

Download Report
Rating
B+

Review of Xebec Adsorption Inc.

DEC 21, 2020 - While the stock can see severe volatility in any short-term period, we think XBC is a name in the renewable energy space that has the potential to reward patient investors over the long-run. Rating initiated at B+.

Download Report